Is tumor bed boost necessary in patients who achieved ypCR following neoadjuvant chemotherapy and breast conserving therapy? (KROG 12-05 and 16-16)
- 주제(키워드) Breast cancer , Neoadjuvant chemotherapy , Tumor bed boost , Radiotherapy
- 주제(기타) Oncology; Obstetrics & Gynecology
- 설명문(일반) [Cho, Won Kyung; Park, Won; Choi, Doo Ho] Sungkyunkwan Univ, Samsung Med Ctr, Dept Radiat Oncol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea; [Kim, Yong Bae; Su, Chang-Ok] Yonsei Univ, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Shin, Kyung Hwan; Chie, Eui Kyu; Kim, Jin Ho] Seoul Natl Univ, Dept Radiat Oncol, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea; [Ahn, Seung Do; Kim, Su Ssan] Univ Ulsan, Asan Med Ctr, Dept Radiat Oncol, Coll Med, Seoul, South Korea; [Kim, Kyubo] Ewha Womans Univ, Dept Radiat Oncol, Sch Med, Seoul, South Korea; [Kim, Jin Hee] Keimyung Univ, Dongsan Med Ctr, Dept Radiat Oncol, Sch Med, Daegu, South Korea; [Ahn, Sung Ja] Chonnam Natl Univ, Dept Radiat Oncol, Med Sch, Gwangju, South Korea; [Lee, Sun Young] Chonbuk Natl Univ, Dept Radiat Oncol, Med Sch, Jeonju, South Korea; [Lee, Jeongshim] Inha Univ Hosp, Dept Radiat Oncol, Incheon, South Korea; [Kim, Sang-Won] Ajou Univ, Dept Radiat Oncol, Sch Med, Suwon, South Korea; [Kim, Sang-Won] Konyang Univ, Dept Radiat Oncol, Coll Med, Daejeon, South Korea; [Kwon, Jeanny] Chungnam Natl Univ, Dept Radiat Oncol, Daejeon, Coll Med, Daejeon, South Korea; [Ahn, Ki Jung] Inje Univ, Dept Radiat Oncol, Busan Paik Hosp, Busan, South Korea; [Shin, Hyun Soo] Bundang CHA Hosp, Dept Radiat Oncol, Seoul, South Korea; [Lee, Hyung Sik] Dong A Univ Hosp, Dept Radiat Oncol, Busan, South Korea; [Lee, Nam Kwon] Korea Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Shin, Kyung Hwan] Natl Canc Ctr, Proton Therapy Ctr, Res Inst & Hosp, Goyang, South Korea
- 등재 SCIE, SCOPUS
- 발행기관 CHURCHILL LIVINGSTONE
- 발행년도 2019
- URI http://www.dcollection.net/handler/ewha/000000160434
- 본문언어 영어
- Published As http://dx.doi.org/10.1016/j.breast.2019.02.010
- PubMed https://pubmed.ncbi.nlm.nih.gov/30844692
초록/요약
Purpose: This multi-institutional study intended to investigate the effect of tumor bed boost in patients who achieved pathologic complete response (ypCR) following neoadjuvant chemotherapy (NAC) and breast-conserving therapy (BCT). Materials and methods: We identified 180 patients who initially had lymph node (LN) metastasis and achieved ypCR (ypT0/isN0) following NAC and BCT from the 13 institutions of the Korean Radiation Oncology Group (KROG) 16-16 and KROG 12-05. The effect of tumor bed boost on loco-regional control (LRC), disease-free survival (DFS), and overall survival (OS) rates was analyzed. Results: In all patients, five-year LRC, DFS and OS rates were 97.5%, 95.4%, and 99.4%, respectively. Tumor bed boost was performed in 158 (87.8%) patients. Advanced N-stage (cN2-3, p = 0.036), close resection margin (p < 0.001), and sentinel lymph node biopsy (p = 0.040) were unfavorable factors for DFS. Tumor bed boost was not a significant factor for LRC, DFS, and OS. Conclusions: This study suggests the benefit of tumor bed boost might be minimal in ypCR patients following NAC and BCT. Larger prospective studies are needed to address this issue. (C) 2019 Published by Elsevier Ltd.
more